A practical reference on analytical standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In conjunction, the Russian Interior Ministry issued an arrest warrant for the International Criminal Court's Prosecutor Karim Ahmad Khan, who was responsible for issuing Putin's arrest warrant in March 2023, while the Prosecutor-General of Russia deemed the environmental organization Greenpeace an "undesirable organization", calling it "a threat to the foundations of the constitutional order and security" of the country for interfering in the "internal affairs of the state" and spreading "anti-Russian propaganda" and calling for economic sanctions. The order prompted Greenpeace to halt its operations in Russia. Yevgeny Roizman, former mayor of Yekaterinburg and opposition politician, was convicted and fined 260,000 rubles ($3245) for discrediting the Russian army over comments made regarding the war in Ukraine. Ukraine was losing some 10,000 drones a month due to Russian electronic warfare according to report by the Royal United Services Institute.
The end point of translational research in medicine is the production of a promising new treatment that can be used clinically. Translational research is conceived due to the elongated time often taken to bring to bear discovered medical idea in practical terms in a health system. It is for these reasons that translational research is more effective in dedicated university science departments or isolated, dedicated research centers. Since 2009, the field has had specialized journals, the American Journal of Translational Research and Translational Research dedicated to translational research and its findings. Translational research in biomedicine is broken down into different stages. In a two-stage model, T1 research, refers to the "bench-to-bedside" enterprise of translating knowledge from the basic sciences into the development of new treatments and T2 research refers to translating the findings from clinical trials into everyday practice, although this model is actually referring to the 2 "roadblocks" T1 and T2. Waldman et al. propose a scheme going from T0 to T5. T0 is laboratory (before human) research. In T1-translation, new laboratory discoveries are first translated to human application, which includes phase I & II clinical trials. In T2-translation, candidate health applications progress through clinical development to engender the evidence base for integration into clinical practice guidelines. This includes phase III clinical trials. In T3-translation, dissemination into community practices happens.
== Reactions == Esters are less reactive than acid halides and anhydrides. As with more reactive acyl derivatives, they can react with ammonia and primary and secondary amines to give amides, although this type of reaction is not often used, since acid halides give better yields.
Sources: en.wikipedia.org
Sven Co-op is a co-op variation of the 1998 first-person shooter Half-Life. The game, initially released as a mod in January 1999, and created by Daniel "Sven Viking" Fearon, enables players to play together on online servers to complete levels, many of which are based on the Half-Life universe but include other genres. In addition to the cooperative gameplay, Sven Co-op includes improvements from the original Half-Life, including improved artificial intelligence for both enemy and allied non-player characters. Since its original release, the project has been overseen by David "Sniper" McDermott. In 2013, Valve, which owns the rights to the Half-Life series, gave the development team the rights to publish the modification as a standalone title on Steam, and further allowed them to distribute the maps and assets of Half-Life to support its release. The standalone release, representing version 5.0 of the mod, was released in January 2016.
Multiple historic and cultural sites, including UNESCO World Heritage Sites, were damaged. The most affected was Chehel Sotoun and its rich ayeneh-kari. On 2 March, a strike on Arg Square damaged nearby Golestan Palace, prompting UNESCO to issue a statement of concern. On 5 March, the Azadi Sport Complex was bombed. An 8 March strike on Falak-ol-Aflak, which was marked with a blue shield emblem, damaged several sections of the site. Strikes on Isfahan on 9 March damaged Naqsh-e Jahan Square, Chehel Sotoun, Ali Qapu, the Shah Mosque, Jameh Mosque, and Teymouri Hall. On 11 March, UNESCO urged protection for Iran's heritage sites and World Heritage Sites that have been damaged or are under high risk due to the war, alongside other historic sites in Israel, Lebanon, and the rest of West Asia. On 17 March, blast waves and shrapnel damaged multiple palaces at Sa'dabad Complex in northern Tehran. Russia's Ministry of Foreign Affairs reported that strikes in Tehran on 1 April damaged the St. Nicholas Orthodox Church and its auxiliary buildings. On 7 April, the Rafi'-Nia synagogue was fully destroyed by the IAF.
Martín-Francés et al. (2026) interpret the molar wear in the Sima de los Huesos hominins as suggestive of a mixed diet including similar proportions of meat and plant foods. Parfitt & Bello (2026) describe a 480,000-years-old knapping tool made on an elephant bone from the Boxgrove Palaeolithic site (United Kingdom), representing the oldest case of an elephant bone being used as a raw material in Europe reported to date. Nicoud et al. (2026) study the chronology of bifacial occurrences from Valle Giumentina (Italy), reporting evidence of shifts in the biface structure within two levels from Marine Isotope Stage 12, and interpret evidence from the studied site as consistent with repeated reinventions of the biface in Europe during the Lower Paleolithic. A study on the Acheulean handaxe variability in southeastern Britain, interpreted as consistent with presence of distinct regional cultural groups during the Marine Isotope Stage 11, is published by White et al. (2026). García-Martínez et al. (2026) provide the first proteomics-based sex identification of a hominin tooth from the Middle Pleistocene of western Europe, using the analysis of the presence of amelogenin to attribute a hominin molar from the Middle Pleistocene site of Ruidera (Spain) to a male individual. Rosas et al.
Sources: en.wikipedia.org
Engrafting an immunodeficient mouse with functional human cells can be achieved by intravenous injections of human cells and tissue into the mouse, and/or creating a genetically modified mouse from human genes. These models have been instrumental in studying human diseases, immune responses, and therapeutic interventions. This section highlights the various humanized mice models developed using the different methods.
== Education == In 1993, Townsend graduated from George Mason University with a Bachelor of Science in Biology and Mathematics. She went on to earn a Master of Science in Molecular Genetics from the same university. She received a doctoral degree from the University of Virginia School of Medicine where she focused on cancer cell biology and metabolism. From 2001 to 2004, she served as a post-doctoral fellow in Pharmacology and Experimental Therapeutics at Fox Chase Cancer Center.
The Convention on Psychotropic Substances was adopted in 1971, entered into force on August 16, 1976, has been joined by 184 countries. It addresses a number of synthetic psychotropic substances, such as amphetamines, barbiturates, and LSD, that had become widely used since World War II, and especially in the 1960s, and were generally not regulated internationally. According to the UNODC, the convention "responded to the diversification and expansion of the spectrum of drugs of abuse and introduced controls over a number of synthetic drugs according to their abuse potential on the one hand and their therapeutic value on the other". The convention classifies the drugs it concerns in a four-schedule system different in the details from the Single Convention schedules.
p3 peptide also known as amyloid β- peptide (Aβ)17–40/42 is the peptide resulting from the α- and γ-secretase cleavage from the amyloid precursor protein (APP). It is known to be the major constituent of diffuse plaques observed in Alzheimer's disease (AD) brains and pre-amyloid plaques in people affected by Down syndrome. However, p3 peptide's role in these diseases is not truly known yet.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.